Noticias Newswire - Hispanic Press Release Distribution Wire Service

The world changed. Your wire should 'tu'

NEW! EDITORIAL FEATURES ARTS & CULTURE AUTOMOTIVE BUSINESS & FINANCE EDUCATION ENTERTAINMENT FAMILY & LIVING FASHION & BEAUTY FOOD & BEVERAGE GENERAL NEWS HEALTH HUMAN INTEREST IMMIGRATION INTERNET & TECHNOLOGY MARKETING/ SOCIAL MEDIA PUBLIC AFFAIRS/GOVERNMENT SPORTS & RECREATION TRAVEL & TOURISM

HUMAN INTEREST

Congressional Hispanic Leadership Institute Announces Series of Voter Forums to Educate, Engage and Empower Millennial Hispanics/Latinos

— The CHLI Red White Y Tu forums will bring together congressional speakers, distinguished civic and community leaders, experts in electoral research and student leaders to discuss the importance of being educated about the political process and the importance of Hispanic/Latino voter participation —

— The panel will be comprised of non-partisan electoral research experts, millennial leaders and a community leader, followed by a question and answer period. Ultimately, millennials are projected to be nearly half (44%) of the Latinos eligible to vote, many of which are either not registered to vote or do not intend to participate in the 2016 Presidential election. Going where these potential Latino voters are, Red, White Y Tu seeks to reach across the country to educate, engage and empower Hispanic/Latino millennial voters. For more info, please CLICK HERE. TO RSVP, please CLICK HERE —

New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint® in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy

— 46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® and MINDACT shows could possibly forgo chemotherapy[i] —

— MammaPrint could change clinical practice by providing critical prognostic information to aid in assessing patients’ risk for distant metastasis and potentially sparing over one hundred thousand women annually[ii] with early-stage breast cancer worldwide from unnecessary toxicities and side effects from chemotherapy and creating considerable cost savings —

— As demonstrated in the MINDACT trial, MammaPrint is now the only FDA-cleared breast cancer prognostic test with the highest level of evidence (1A) for its clinical utility to aid correctly identifying Low Risk patients —